Cargando…

Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States

Recent evidence suggests that some new SARS-CoV-2 variants with spike mutations, such as P.1 (Gamma) and B.1.617.2 (Delta), exhibit partial immune evasion to antibodies generated by natural infection or vaccination. By considering the Gamma and Delta variants in a multi-variant transmission dynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sah, Pratha, Vilches, Thomas N., Shoukat, Affan, Fitzpatrick, Meagan C., Pandey, Abhishek, Singer, Burton H., Moghadas, Seyed M., Galvani, Alison P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132270/
https://www.ncbi.nlm.nih.gov/pubmed/34013295
http://dx.doi.org/10.1101/2021.05.10.21256996
_version_ 1783694883454713856
author Sah, Pratha
Vilches, Thomas N.
Shoukat, Affan
Fitzpatrick, Meagan C.
Pandey, Abhishek
Singer, Burton H.
Moghadas, Seyed M.
Galvani, Alison P.
author_facet Sah, Pratha
Vilches, Thomas N.
Shoukat, Affan
Fitzpatrick, Meagan C.
Pandey, Abhishek
Singer, Burton H.
Moghadas, Seyed M.
Galvani, Alison P.
author_sort Sah, Pratha
collection PubMed
description Recent evidence suggests that some new SARS-CoV-2 variants with spike mutations, such as P.1 (Gamma) and B.1.617.2 (Delta), exhibit partial immune evasion to antibodies generated by natural infection or vaccination. By considering the Gamma and Delta variants in a multi-variant transmission dynamic model, we evaluated the dominance of these variants in the United States (US) despite mounting vaccination coverage and other circulating variants. Our results suggest that while the dominance of the Gamma variant is improbable, the Delta variant would become the most prevalent variant in the US, driving a surge in infections and hospitalizations. Our study highlights the urgency for accelerated vaccination and continued adherence to non-pharmaceutical measures until viral circulation is driven low.
format Online
Article
Text
id pubmed-8132270
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-81322702021-05-20 Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States Sah, Pratha Vilches, Thomas N. Shoukat, Affan Fitzpatrick, Meagan C. Pandey, Abhishek Singer, Burton H. Moghadas, Seyed M. Galvani, Alison P. medRxiv Article Recent evidence suggests that some new SARS-CoV-2 variants with spike mutations, such as P.1 (Gamma) and B.1.617.2 (Delta), exhibit partial immune evasion to antibodies generated by natural infection or vaccination. By considering the Gamma and Delta variants in a multi-variant transmission dynamic model, we evaluated the dominance of these variants in the United States (US) despite mounting vaccination coverage and other circulating variants. Our results suggest that while the dominance of the Gamma variant is improbable, the Delta variant would become the most prevalent variant in the US, driving a surge in infections and hospitalizations. Our study highlights the urgency for accelerated vaccination and continued adherence to non-pharmaceutical measures until viral circulation is driven low. Cold Spring Harbor Laboratory 2021-08-18 /pmc/articles/PMC8132270/ /pubmed/34013295 http://dx.doi.org/10.1101/2021.05.10.21256996 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Sah, Pratha
Vilches, Thomas N.
Shoukat, Affan
Fitzpatrick, Meagan C.
Pandey, Abhishek
Singer, Burton H.
Moghadas, Seyed M.
Galvani, Alison P.
Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
title Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
title_full Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
title_fullStr Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
title_full_unstemmed Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
title_short Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
title_sort quantifying the potential dominance of immune-evading sars-cov-2 variants in the united states
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132270/
https://www.ncbi.nlm.nih.gov/pubmed/34013295
http://dx.doi.org/10.1101/2021.05.10.21256996
work_keys_str_mv AT sahpratha quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates
AT vilchesthomasn quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates
AT shoukataffan quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates
AT fitzpatrickmeaganc quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates
AT pandeyabhishek quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates
AT singerburtonh quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates
AT moghadasseyedm quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates
AT galvanialisonp quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates